A qualitative study of insurers' coverage for mifepristone-induced abortion.
In this qualitative evaluation of 14 U.S. health insurers' coverage policies concerning mifepristone-induced medical abortion, the findings suggest that a significant proportion of health plans do not include evidence-based clinical information obtained from recent research, data, and practice. This omission may hinder the adoption of new, evidence-based protocols for medical abortion by physicians. A model coverage policy that contains comprehensive clinical information regarding appropriate clinical regimens for mifepristone is provided as an example for insurers and others in the field.
Gemperli
Marcel P
MP
SCF, San Francisco, California 94143-1744, USA. gouldh@obgyn.ucsf.edu
Stewart
Felicia H
FH
Phillips
Kathryn A
KA
Sakowski
Julie
J
Van Bebber
Stephanie
S
Bergthold
Linda
L
D000028:Abortion, Induced / Q000191:economics*; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D019458:Insurance Coverage; D008329:Managed Care Programs; D015735:Mifepristone / Q000008:administration & dosage* / Q000191:economics; D011247:Pregnancy; D036301:Qualitative Research; D014481:United States
D015735:Mifepristone